Get started
Author

Nektaria Alexandri

Observed names: Alexandri, Nektaria, N Alexandri, N. Alexandri, Nektaria Alexandri (5919553)
Observed institutions: Inserm, Merck KGaA, Darmstadt (Germany), Assistance Publique – Hôpitaux de Paris, Institut de Myologie, Pitié-Salpêtrière Hospital, Institut du Cerveau, Université Pierre-et-Marie-Curie, Merck Healthcare KGaA, Darmstadt (Germany)
ORCID: 0000-0002-9806-8358
Observed ORCID: 0000-0002-9806-8358
OpenAlex ID: A5007546716
Identification of an Agrin Mutation that Causes Congenital Myasthenia and Affects Synapse Function
2009 · Caroline Huzé, Stéphanie Bauché, et al. · The American Journal of Human Genetics · 172
PDF
Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7
2009 · A. Ben Ammar, F. Petit, et al. · Journal of Neurology · 81
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
2021 · Nicola De Stefano, Maria Pia Sormani, et al. · Multiple Sclerosis Journal · 33
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
2021 · Elisabeth G Celius, Heidi Thompson, et al. · Patient Preference and Adherence · 28
PDF
Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
2018 · David Yeandle, Peter Rieckmann, et al. · Neurology and Therapy · 28
PDF
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
2019 · Celia Oreja-Guevara, Stanca Potra, et al. · Advances in Therapy · 27
PDF
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
2023 · Bruno Brochet, Alessandra Solari, et al. · Multiple Sclerosis Journal · 24
PDF
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
2022 · Rosa Cortese, Marco Battaglini, et al. · European Journal of Neurology · 22
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
2021 · Bruno Brochet, Raymond Hupperts, et al. · Multiple Sclerosis and Related Disorders · 18
PDF
Caregiver Involvement in MS: Duty or Disruption?
2021 · Jürg Kesselring, Alexey Boyko, et al. · Neurology and Therapy · 11
PDF
What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation
2023 · Sarah A. Morrow, Paola Kruger, et al. · Neurology and Therapy · 8
PDF
Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
2019 · Patrick Vermersch, Jane Shanahan, et al. · Neurology and Therapy · 8
PDF
Identification of an Agrin Mutation that Causes Congenital Myasthenia and Affects Synapse Function
2009 · Caroline Huzé, Stéphanie Bauché, et al. · The American Journal of Human Genetics · 8
PDF
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
2023 · Amit Bar-Or, Anne H Cross, et al. · Multiple Sclerosis Journal · 6
PDF
Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets
2022 · Alessio Signori, Marta Ponzano, et al. · European Journal of Neurology · 6
Cognitive impairment and its impact on employment: A qualitative interview-based study involving healthcare professionals and people living with multiple sclerosis
2024 · David Yeandle, Sarah A. Morrow, et al. · Multiple Sclerosis and Related Disorders · 5
PDF
Post-Approval Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: 2023 Update
2023 · Gavin Giovannoni, Thomas Leist, et al. · Multiple Sclerosis and Related Disorders · 4
Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion
2016 · Nikolaos Grigoriadis, Michael Linnebank, et al. · Expert Opinion on Pharmacotherapy · 4
Clinical Outcomes in Patients With COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update (P11-4.005)
2022 · Victoria Yavorskaya, Radmila Karan, et al. · Neurology · 3
Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS
2023 · Alessandra Solari, Xavier Montalban, et al. · Multiple Sclerosis and Related Disorders · 2
Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis (1925)
2021 · Bruno Brochet, Raymond Hupperts, et al. · Neurology · 2
THUR 172 Phase iv study of cladribine tablets and quality of life: clarify-ms
2018 · S Schippling, D Langdon, et al. · Journal of Neurology Neurosurgery & Psychiatry · 2
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
2026 · Bruno Brochet, Dawn Langdon, et al. · Neurology and Therapy · 1
PDF
Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1-11.013)
2025 · Konrad Rejdak, James F. Howard, et al. · Neurology · 1
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
2024 · Bruno Brochet, Alessandra Solari, et al. · Neurodegenerative Disease Management · 1
PDF
Works count: 55
Citation count: 507
H-index: 10
I10-index: 10
Year
Topic
Type